Marco Busutti

Verified @live.com

Nephrology, Dialysis and Renal Transplant Unit
IRCCS Azienda Ospedaliero-universitaria di Bologna

Marco Busutti


         Download Compact PDF  
https://researchid.co/marco.busutti
34

Scopus Publications

Scopus Publications

  • Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study
    Johan Noble, Giorgia Comai, Valeria Corredetti, Reda Laamech, Celine Dard, Thomas Jouve, Diane Giovannini, Audrey Le Gouellec, Shivani Wadnerkar, Paolo Cravedi, Della Apuzzo, Daniele Vetrano, Marco Busutti, Chiara Abenavoli, Paolo Malvezzi, Lionel PE Rostaing, Gaetano Lamanna
    Transplant International, 2025
    Chronic-active antibody mediated rejection (caAMR) is the leading causes of long-term kidney graft failure. Tocilizumab (TCZ), an anti-IL-6 receptor antibody, has been suggested as a treatment, but data are conflicting. We retrospectively studied consecutive adult kidney transplant recipients with caAMR or microvascular inflammation (MVI) without Donor-Specific Antibodies (DSA) and without C4d deposition (MVI + DSA-C4d-), who received TCZ as first-line therapy in two European centers. Estimated glomerular filtration rate (eGFR) and DSA were assessed one-year before and after TCZ initiation. The study included 64 patients who received TCZ between July 2018 and September 2023. The eGFR trajectory significantly decreased after TCZ treatment (−1.2 ± 0.2 vs. 0.03 ± 0.2 mL/min/1.73 m2/month pre- vs. post-TCZ, respectively; p = 0.001). The percentage of patients with DSA decreased from 63.9% to 38.9% (p < 0.001), and the average MFI decreased from 9,537 to 7,250 (p = 0.001). In multivariate analysis, younger age (OR = 0.95, p = 0.02), MVI + DSA-C4d- phenotype (OR = 5.2, p = 0.01), and lower chronic glomerulopathy score (OR = 4.5, p = 0.02) were associated with TCZ response (trajectory ≥0 after TCZ). Patient survival was 98.4%, and graft survival was 93.7% at one-year. First-line TCZ therapy for caAMR or MVI + DSA-C4d- is associated with an improvement of eGFR trajectories, reduced DSA numbers and MFI and histological inflammation in glomeruli. These data suggest a potential benefit of TCZ in these settings.
  • Renal Benefits of CO2 as a Contrast Media for EVAR Procedures: New Perspectives on 1 Year Outcomes
    Marco Busutti, Alice Sensoni, Andrea Vacirca, Chiara Abenavoli, Chiara Donadei, Anna Laura Croci Chiocchini, Matteo Righini, Giorgia Comai, Alessia Pini, Gianluca Faggioli, Enrico Gallitto, Gaetano La Manna, Mauro Gargiulo
    Journal of Endovascular Therapy, 2024
    Background and Objectives: Endovascular aneurism repair (EVAR) is a minimally invasive alternative to open surgery for the treatment of abdominal aortic aneurysm. Iodine contrast medium (ICM) is considered the gold standard, at the high price of related nephrotoxicity and allergic reactions. Carbon dioxide (CO2) has been suggested as an alternative non-nephrotoxic contrast media agent. We aimed to evaluate the safety and the renal impact of the administration of CO2, compared with ICM in EVAR procedures. Design, Setting, Participants, and Measurements: We retrospectively reviewed data of patients who underwent EVAR at the Vascular Surgery Department of the Sant’Orsola Hospital in Bologna. Estimated glomerular filtration rate (eGFR) was evaluated before intervention, immediately after and at 12 months. Results: In total, 22 patients received CO2 and low-dose ICM (CO2 Group) and 22 received standard ICM (Control Group), matched for clinical characteristics and renal function at the time of procedure. Pre and post-operative renal function values (eGFR) were compared between the two groups: in the immediate post-operative the group treated with CO2 and low-dose ICM globally showed a slight improvement in renal function (mean eGFR +5.10%±3.2), meanwhile the group treated with standard dose of ICM presented a significant worsening of renal function compared with pre-procedure values (mean eGFR −9.65%±4). Incidence of post-contrast acute kidney injury (PC-AKI) was 9% in the CO2 group vs 27% in the Control group. At 12 months, the renal impairment was significantly greater in the ICM group than in the CO2 group (mean eGFR decrease −19.2%±11.1 and −7.40%±3.5, respectively). Conclusions: Administration of either CO2 alone or along with low-dose ICM showed to be safer than full-dose ICM alone, lowering the incidence of PC-AKI in patients undergoing EVAR. Unexpectedly, our study revealed also a significant worsening of renal function in patients treated with standard dose of ICM in 1-year follow-up, introducing the concept that acute renal damage caused by ICM could elicit a chronic injury process that affect long-term renal outcomes. Clinical Impact Evaluating the safety and the renal impact of the administration of CO2, compared to Iodinate Contrast Medium, in EVAR procedures represents a first step in order to further tayloring medical procedures on patients characteristics. Our findings can guide the clinicians and surgeons in the procedures choice, not considering only the immediate effect of ICM on renal function but also the potential long-term effects.
  • Efficacy and safety of switching from Eculizumab to Ravulizumab for the maintenance of aHUS remission after kidney transplant: a preliminary experience
    Marco Busutti, Federica Maritati, Greta Borelli, Claudia Bini, Valeria Corradetti, Vania Cuna, Chiara Abenavoli, Michele Provenzano, Matteo Ravaioli, Gaetano La Manna, Giorgia Comai
    Journal of Nephrology, 2024
    No abstract available
  • “Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy
    Federica Maritati, Valeria Corradetti, Claudia Bini, Michele Provenzano, Vania Cuna, et al.
    Kidney International Reports, 2024
    IntroductionPost-transplant thrombotic microangiopathy (PT-TMA) is an uncommon event that characterizes approximately 3-14% of kidney transplants (KT), and that is associated with a higher risk of delayed graft function and graft loss. PT-TMA occurs more frequently within the first three months after transplant and can be a manifestation of de novo disease or the recurrence of previous atypical hemolytic uremic syndrome (aHUS). Abnormalities in complement regulation genes could explain the increased susceptibility of some patients to PT-TMA. Eculizumab is a humanized monoclonal antibody that inhibits the formation of the membrane attack complex C5b-9. The aim of this study is to evaluate the efficacy of eculizumab as treatment for PT-TMA.MethodsWe retrospectively analyzed clinical records of 45 KT patients who received eculizumab immediately after the clinical diagnosis of PT-TMA.ResultsKidney biopsy was performed in 91.1% of patients and complement genetic study in 64.4%. 85.4% of kidney biopsies showed signs of TMA; genetic analysis revealed one pathogenetic variant, two variants of uncertain significance, one likely benign variant, 8 risk polymorphisms, 27 risk haplotypes.After two weeks from the treatment starting, hemoglobin and platelets significantly increased. A remarkable improvement in kidney function was also observed. After six months, 28.8% of patients had a complete renal recovery while 44.4% had a partial recovery.ConclusionThis is, to our knowledge, the largest series of KT patients with PT-TMA treated with eculizumab. These data suggest that eculizumab is associated with a normalization of hemolysis indices and an important and progressive improvement of graft function.
  • Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement
    Matteo Righini, Raul Mancini, Marco Busutti, Andrea Buscaroli
    International Journal of Molecular Sciences, 2024
    Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder, but kidneys are not the only organs involved in this systemic disorder. Individuals with the condition may display additional manifestations beyond the renal system, involving the liver, pancreas, and brain in the context of cystic manifestations, while involving the vascular system, gastrointestinal tract, bones, and cardiac valves in the context of non-cystic manifestations. Despite kidney involvement remaining the main feature of the disease, thanks to longer survival, early diagnosis, and better management of kidney-related problems, a new wave of complications must be faced by clinicians who treated patients with ADPKD. Involvement of the liver represents the most prevalent extrarenal manifestation and has growing importance in the symptom burden and quality of life. Vascular abnormalities are a key factor for patients’ life expectancy and there is still debate whether to screen or not to screen all patients. Arterial hypertension is often the earliest onset symptom among ADPKD patients, leading to frequent cardiovascular complications. Although cardiac valvular abnormalities are a frequent complication, they rarely lead to relevant problems in the clinical history of polycystic patients. One of the newest relevant aspects concerns bone disorders that can exert a considerable influence on the clinical course of these patients. This review aims to provide the “state of the art” among the extrarenal manifestation of ADPKD.
  • Identification of asymptomatic Leishmania infection in patients undergoing kidney transplant using multiple tests
    Alessandro Deni, Alessandra Mistral De Pascali, Margherita Ortalli, Emma Balducelli, Michele Provenzano, Francesca Ferrara, Marco Busutti, Gaetano La Manna, Lorenzo Zammarchi, Alessandro Bartoloni, Leonardo Caroti, Ana Victoria Ibarra-Meneses, Eugenia Carrillo, Giorgia Comai, Stefania Varani
    International Journal of Infectious Diseases, 2024
    OBJECTIVES: In immunocompromised patients, asymptomatic Leishmania infection can reactivate, and evolve to severe disease. To date, no test is considered the gold standard for the identification of asymptomatic Leishmania infection. A combination of methods was employed to screen for Leishmania infection in patients undergoing kidney transplant (KT). METHODS: We employed polymerase chain reaction for the detection of parasitic DNA in peripheral blood, Western blot to identify serum immunoglobulin G and whole blood assay to detect cytokines/chemokines after stimulation of whole blood with parasitic antigen. RESULTS: One-hundred twenty patients residing in Italy were included in the study at the time of KT. Each patient that tested positive to at least one test was considered as Leishmania positive. Fifty out of 120 patients (42%) tested positive for one or more tests. The detection of specific cell-mediated response (32/111, 29%) was the most common marker of Leishmania infection, followed by a positive serology (24/120, 20%). Four patients (3%) harbored parasitic DNA in the blood. CONCLUSION: Our findings underline the high prevalence of asymptomatic Leishmania infection in patients undergoing KT in Italy, who are potentially at-risk for parasite reactivation and can benefit from an increased vigilance. Understanding the clinical relevance of these findings deserves further studies.
  • Immunosuppressive therapy and oral anticoagulation in kidney transplant recipients: Direct oral anticoagulants versus vitamin-k antagonists
    Francesco Santoro, Annalisa Casanova, Simona Simone, Carlo Alfieri, Adele Falcone, Andrea Dello Strologo, Valeria Grandinetti, Marco Busutti, Giorgia Comai, Tommaso Maria Marvulli, Maria Grazia Zippo, Giuseppe Castellano, Gaetano La Manna, Loreto Gesualdo, Grandaliano Giuseppe, Francesco Pesce
    European Journal of Internal Medicine, 2024
  • Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn's Disease
    Marco Busutti, Olga Baraldi, Clara Valentina Porcu, Gianluca Samele, Anita Campus, Valeria Grandinetti, Claudia Bini, Michele Provenzano, Nikolas Dussias, Fernando Rizzello, Paolo Gionchetti, Gaetano La Manna, Giorgia Comai
    Kidney International Reports, 2023
    Crohn’s disease (CD) and ulcerative colitis are chronic and idiopathic inflammatory bowel diseases, characterized by gastrointestinal symptoms such as abdominal pain, fecal urgency, and diarrhea1,2; and extra intestinal manifestations that may involve almost any organ including the kidney. The most common renal extra intestinal manifestations are nephrolithiasis, tubulointerstitial nephritis, glomerulonephritis, and amyloidosis. In addition, kidney damage in patients with CD may result from dehydration, long-term malnutrition, anemia, and side-effects of medical therapy.
  • Using machine learning to predict antibody response to SARS-CoV-2 vaccination in solid organ transplant recipients: the multicentre ORCHESTRA cohort
    Maddalena Giannella, Manuel Huth, Elda Righi, Jan Hasenauer, Lorenzo Marconi, Angelina Konnova, Akshita Gupta, An Hotterbeekx, Matilda Berkell, Zaira R. Palacios-Baena, Maria Cristina Morelli, Mariarosa Tamè, Marco Busutti, Luciano Potena, Elena Salvaterra, Giuseppe Feltrin, Gino Gerosa, Lucrezia Furian, Patrizia Burra, Salvatore Piano, Umberto Cillo, Mara Cananzi, Monica Loy, Gianluigi Zaza, Francesco Onorati, Amedeo Carraro, Fiorella Gastaldon, Maurizio Nordio, Samir Kumar-Singh, Jesús Rodríguez Baño, Tiziana Lazzarotto, Pierluigi Viale, Evelina Tacconelli
    Clinical Microbiology and Infection, 2023
  • Relationship between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients: The CONTRAST Cohort
    Cecilia Bonazzetti, Beatrice Tazza, Dino Gibertoni, Zeno Pasquini, Natascia Caroccia, Francesca Fanì, Giacomo Fornaro, Renato Pascale, Matteo Rinaldi, Beatrice Miani, Chiara Gamberini, Maria Cristina Morelli, Mariarosa Tamé, Marco Busutti, Giorgia Comai, Luciano Potena, Laura Borgese, Elena Salvaterra, Tiziana Lazzarotto, Luigia Scudeller, Pierluigi Viale, Maddalena Giannella, Michela Di Chiara, Maria Eugenia Giacomini, Oana Vatamanu, Lorenzo Marconi, Clara Solera Horna, Caterina Campoli, Michele Bartoletti, Linda Bussini, Fabio Trapani, Luciano Attard, Milo Gatti, Antonio Gramegna, Gaetano La Manna, Valeria Grandinetti, Marcello Demetri, Simona Barbuto, Chiara Abenavoli, Giovanni Vitale, Laura Turco, Matteo Ravaioli, Matteo Cescon, Valentina Bertuzzo, Paola Messina, Alessandra Trombi, Marco Masetti, Paola Prestinenzi, Mario Sabatino, Laura Giovannini, Aloisio Alessio, Antonio Russo, Maria Francesca Scuppa, Giampiero Dolci, Gianmaria Paganelli, Liliana Gabrielli, Matteo Pavoni, Marta Leone, Federica Lanna, and
    Clinical Infectious Diseases, 2023
    Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in solid organ transplant (SOT) recipients is associated with poorer antibody response (AbR) compared with non-SOT recipients. However, its impact on the risk of breakthrough infection (BI) has yet to be assessed. Methods Single-center prospective longitudinal cohort study enrolling adult SOT recipients who received SARS-CoV-2 vaccination during a 1-year period (February 2021 – January 2022), end of follow-up April 2022. Patients were tested for AbR at multiple time points. The primary end-point was BI (laboratory-confirmed SARS-CoV-2 infection ≥14 days after the second dose). Immunization (positive AbR) was considered an intermediate state between vaccination and BI. Probabilities of being in vaccination, immunization, and BI states were obtained for each type of graft and vaccination sequence using multistate survival analysis. Then, multivariable logistic regression was performed to analyze the risk of BI related to AbR levels. Results 614 SOT (275 kidney, 163 liver, 137 heart, 39 lung) recipients were included. Most patients (84.7%) received 3 vaccine doses. The first 2 consisted of BNT162b2 and mRNA-1273 in 73.5% and 26.5% of cases, respectively. For the third dose, mRNA-1273 was administered in 59.8% of patients. Overall, 75.4% of patients reached immunization and 18.4% developed BI. Heart transplant recipients showed the lowest probability of immunization (0.418) and the highest of BI (0.323); all mRNA-1273 vaccine sequences showed the highest probability of immunization (0.732) and the lowest of BI (0.098). Risk of BI was higher for non–high-level AbR, younger age, and shorter time from transplant. Conclusions SOT patients with non–high-level AbR and shorter time from transplantation and heart recipients are at highest risk of BI.
  • Updated diagnosis and graft involvement for visceral leishmaniasis in kidney transplant recipients: a case report and literature review
    Marco Busutti, Alessandro Deni, Alessandra Mistral De Pascali, Margherita Ortalli, Luciano Attard, Bianca Granozzi, Benedetta Fabbrizio, Gaetano La Manna, Giorgia Comai, Stefania Varani
    Infection, 2023
  • Renal Vessel Extension With Cryopreserved Vascular Grafts: Overcoming Surgical Pitfalls in Living Donor Kidney Transplant
    Guido Fallani, Lorenzo Maroni, Chiara Bonatti, Giorgia Comai, Marina Buzzi, Vania Cuna, Francesco Vasuri, Francesca Caputo, Enrico Prosperi, Federico Pisani, Beatrice Pisillo, Ludovica Maurino, Federica Odaldi, Valentina Rosa Bertuzzo, Francesco Tondolo, Marco Busutti, Chiara Zanfi, Massimo Del Gaudio, Gaetano La Manna, Matteo Ravaioli
    Transplant International, 2023
  • A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome
    Marina Vivarelli, Manuela Colucci, Mattia Algeri, Federica Zotta, Francesco Emma, Ines L’Erario, Marco Busutti, Stefano Rota, Chiara Capelli, Martino Introna, Marta Todeschini, Federica Casiraghi, Annalisa Perna, Tobia Peracchi, Andrea De Salvo, Nadia Rubis, Franco Locatelli, Giuseppe Remuzzi, Piero Ruggenenti
    Jci Insight, 2023
  • Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience
    Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
    Lung Cancer, 2022
  • The process of transition from pediatric to adult healthcare services for nephrological patients: Recommendations vs. reality—A single center experience
    Dorella Scarponi, Gabriella Cangini, Andrea Pasini, Claudio La Scola, Francesca Mencarelli, Cristina Bertulli, Domenico Amabile, Marco Busutti, Gaetano La Manna, Andrea Pession
    Frontiers in Pediatrics, 2022
  • Up-Date on Diabetic Nephropathy
    Maria Chiara Pelle, Michele Provenzano, Marco Busutti, Clara Valentina Porcu, Isabella Zaffina, Lucia Stanga, Franco Arturi
    Life, 2022
  • Kidney transplantation in systemic sclerosis: Advances in graft, disease, and patient outcome
    Federica Maritati, Michele Provenzano, Sarah Lerario, Valeria Corradetti, Claudia Bini, Marco Busutti, Valeria Grandinetti, Vania Cuna, Gaetano La Manna, Giorgia Comai
    Frontiers in Immunology, 2022
  • Everolimus-associated alveolar hemorrage relapse after drug discontinuation in a kidney transplant recipient
    Marco Busutti, Alessandra Cingolani, Filippo Natali, Maria Mattiotti, Valeria Grandinetti, Olga Baraldi, Giorgia Comai, Piero Candoli, Gaetano La Manna
    Journal of Nephrology, 2022
  • Wide Range Applications of Spirulina: From Earth to Space Missions
    Giacomo Fais, Alessia Manca, Federico Bolognesi, Massimiliano Borselli, Alessandro Concas, Marco Busutti, Giovanni Broggi, Pierdanilo Sanna, Yandy Marx Castillo-Aleman, René Antonio Rivero-Jiménez, Antonio Alfonso Bencomo-Hernandez, Yendry Ventura-Carmenate, Michela Altea, Antonella Pantaleo, Gilberto Gabrielli, Federico Biglioli, Giacomo Cao, Giuseppe Giannaccare
    Marine Drugs, 2022
  • Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort
    Maddalena Giannella, Elda Righi, Renato Pascale, Matteo Rinaldi, Natascia Caroccia, Chiara Gamberini, Zaira R. Palacios-Baena, Giulia Caponcello, Maria Cristina Morelli, Mariarosa Tamè, Marco Busutti, Giorgia Comai, Luciano Potena, Elena Salvaterra, Giuseppe Feltrin, Umberto Cillo, Gino Gerosa, Mara Cananzi, Salvatore Piano, Elisa Benetti, Patrizia Burra, Monica Loy, Lucrezia Furian, Gianluigi Zaza, Francesco Onorati, Amedeo Carraro, Fiorella Gastaldon, Maurizio Nordio, Samir Kumar-Singh, Mahsa Abedini, Paolo Boffetta, Jesús Rodríguez-Baño, Tiziana Lazzarotto, Pierluigi Viale, Evelina Tacconelli, and
    Microorganisms, 2022
  • Impact of the Type of Dialysis on Time to Transplantation: Is It Just a Matter of Immunity?
    Matteo Righini, Irene Capelli, Marco Busutti, Concettina Raimondi, Giorgia Comai, Gabriele Donati, Maria Laura Cappuccilli, Matteo Ravaioli, Pasquale Chieco, Gaetano La Manna
    Journal of Clinical Medicine, 2022
  • Current Perspectives in ABO-Incompatible Kidney Transplant
    Federica Maritati, Claudia Bini, Vania Cuna, Francesco Tondolo, Sarah Lerario, Valeria Grandinetti, Marco Busutti, Valeria Corradetti, Gaetano La Manna, Giorgia Comai
    Journal of Inflammation Research, 2022
  • Multidisciplinarity in Transition Pathways for Patients With Kidney Disease: The Current State of Play
    Dorella Scarponi, Viviana Cammaroto, Andrea Pasini, Claudio La Scola, Francesca Mencarelli, Cristina Bertulli, Marco Busutti, Gaetano La Manna, Andrea Pession
    Frontiers in Pediatrics, 2021
  • Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome
    Marco Busutti, Francesca Diomedi-Camassei, Roberta Donadelli, Caterina Mele, Francesco Emma, Marina Vivarelli
    Kidney International Reports, 2021
  • Screening strategies for the diagnosis of asymptomatic Leishmania infection in dialysis patients as a model for kidney transplant candidates
    Giorgia Comai, Alessandra Mistral De Pascali, Marco Busutti, Silvia Morini, Margherita Ortalli, Diletta Conte, Maria Carla Re, Gaetano La Manna, Stefania Varani
    Journal of Nephrology, 2021
  • Kidney transplant from donors after cardiac death (DCD): Monocentric experience and literature review
    Giornale Italiano Di Nefrologia, 2019
  • A questionnaire survey of radiological diagnosis and management of renal dysplasia in children
    Giovanni Montini, , Marco Busutti, Fatos Yalcinkaya, Adrian S. Woolf, Stefanie Weber
    Journal of Nephrology, 2018
  • Acute granulomatous interstitial nephritis and ulcerative colitis: A case report and literature review
    Giorgia Comai, Olga Baraldi, Vania Cuna, Valeria Corradetti, Maria Cappuccilli, Marco Busutti, Deborah Malvi, Benedetta Fabbrizio, Massimo Campieri, Gaetano La Manna
    Italian Journal of Medicine, 2018
  • The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition
    Andrea Solazzo, Francesca Testa, Silvia Giovanella, Marco Busutti, Luciana Furci, Paola Carrera, Maurizio Ferrari, Giulia Ligabue, Giacomo Mori, Marco Leonelli, Gianni Cappelli, Riccardo Magistroni
    Plos One, 2018
  • Membranous glomerulonephritis (MGN), ongoing studies
    Giornale Italiano Di Nefrologia Organo Ufficiale Della Societa Italiana Di Nefrologia, 2017
  • Comparison of Total Kidney Volume Quantification Methods in Autosomal Dominant Polycystic Disease for a Comprehensive Disease Assessment
    Dario Turco, Marco Busutti, Renzo Mignani, Riccardo Magistroni, Cristiana Corsi
    American Journal of Nephrology, 2017
  • Successful dual kidney transplantation after hypothermic oxygenated perfusion of discarded human kidneys
    Matteo Ravaioli, Vanessa De Pace, Giorgia Comai, Marco Busutti, Massimo Del Gaudio, Annalisa Amaduzzi, Alessandro Cucchetti, Antonio Siniscalchi, Gaetano La Manna, Antonietta A.D. D’Errico, Antonio Daniele Pinna
    American Journal of Case Reports, 2017
  • Chronic kidney disease
    Francesca Mencarelli, Marco Busutti, Giovanni Montini
    Pediatric Urology Contemporary Strategies from Fetal Life to Adolescence, 2015
  • Mineral metabolism in European children living with a renal transplant: A European society for paediatric nephrology/European renal association–european dialysis and transplant association registry study
    Marjolein Bonthuis, Marco Busutti, Karlijn J. van Stralen, Kitty J. Jager, Sergey Baiko, Sevcan Bakkaloğlu, Nina Battelino, Maria Gaydarova, Bruno Gianoglio, Paloma Parvex, Clara Gomes, James G. Heaf, Ludmila Podracka, Dafina Kuzmanovska, Maria S. Molchanova, Tatiana E. Pankratenko, Fotios Papachristou, György Reusz, Maria José Sanahuja, Rukshana Shroff, Jaap W. Groothoff, Franz Schaefer, Enrico Verrina
    Clinical Journal of the American Society of Nephrology, 2015